Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: A prospective study

Purpose: To evaluate health-related duality of life (HRQOL) in adults treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem-cell transplantation 1 year after transplantation, using data from concurrent lymphoma patients receiving combination chemotherapy (CT) as a reference. Materials and Methods: Forty-one leukemia patients (SCT group), 51 lymphoma patients (ASCT group), and 85 CT patients completed the European Organisation for Research and treatment of Cancer QLQ-C30 questionnaire at baseline and after 1 year. Results: The SCT group (median age, 36 years) had better functioning scores and less symptomatology at baseline compared with the ASCT (median age, 41 years) and CT (median age, 37 years) groups. Statistically significant differences of 10 or more points on the 0 to 100 scales were found for 10 of 15 scales and items (P less than or equal to.01) between the SCT and ASCT groups. Global quality of life (79 v 58, P <.0001), role function (83 v 65, P =.001), sleep disturbances (6 v 28, P <.0001), and fatigue (25 v 44, P =.0001) deviated most. The differences were 10 or more points for seven of 15 scales and items comparing the SCT and CT groups, with sleep disturbances (6 v 35, P <.0001) and pain (11 v 29, P <.01) deviating most. Differences across groups were smaller after 1 year; cognitive function was the only scale with a statistically significant difference (ASCT 80 v CT 89; P =.002). Patterns of change in HRQOL scores were different between groups during follow-vp. A great improvement was found in the ASCT group (P <.01 for emotional and role function, fatigue, appetite, and constipation), whereas no significant changes were observed for the SCT group, Conclusion: Prospective studies with extended follow-up periods are necessary to separate a slow recovery process from more permanently reduced HRQOL after transplantation and to examine the late side effects from previous treatment. (C) 1999 by American Society of Clinical Oncology.